Amyloid β-Peptide (10-20) (Human) Mechanistic Insights, Clin

Amyloid β-Peptide (10-20) (Human): Mechanistic Insights, Clinical Value, and Research Applications in Neurodegenerative Disease

Introduction
Amyloid β-peptides (Aβ) are central to the pathogenesis of Alzheimer’s disease (AD) and related neurodegenerative disorders. Among the various fragments derived from the amyloid precursor protein (APP), Amyloid β-Peptide (10-20) (human) represents a specific sequence (YEVHHQKLVFF) within the full-length Aβ peptide. This segment is of particular interest due to its involvement in β-sheet formation, aggregation propensity, and interaction with cellular components implicated in neurotoxicity (Haass & Selkoe, 2007, Neuron). Understanding the properties and biological effects of Aβ(10-20) is crucial for elucidating the molecular mechanisms underlying amyloidogenesis and for developing targeted therapeutic strategies.

The mechanism of action of Aβ(10-20) centers on its ability to self-assemble into oligomers and fibrils, processes that are believed to drive synaptic dysfunction and neuronal death in AD (Benilova et al., 2012, Nat Neurosci). The peptide’s sequence contains hydrophobic and histidine-rich motifs, facilitating metal ion binding and aggregation. As a research tool, synthetic Aβ(10-20) enables the dissection of aggregation pathways, toxicity mechanisms, and the screening of aggregation inhibitors.

[Related: epoxomycin] Clinical Value and Applications
The clinical value of Amyloid β-Peptide (10-20) (human) lies in its utility as a model system for studying amyloid aggregation, toxicity, and therapeutic intervention. While the peptide itself is not used as a therapeutic agent, it serves as a critical reagent in preclinical research, enabling the following applications:

1. **Aggregation Studies:** Aβ(10-20) is used to model the early stages of amyloid aggregation, providing insights into nucleation and elongation mechanisms (Bitan et al., 2003, J Biol Chem).
2. **Neurotoxicity Assays:** The peptide is employed in in vitro and in vivo models to evaluate cytotoxic effects on neuronal cells, mimicking aspects of AD pathology (Walsh et al., 2002, Nature).
3. **Screening of Inhibitors:** Aβ(10-20) serves as a substrate for high-throughput screening of small molecules, peptides, and antibodies that inhibit aggregation or toxicity (Necula et al., 2007, J Biol Chem).
4. **Biophysical Characterization:** The fragment is used in NMR, mass spectrometry, and fluorescence assays to study conformational dynamics, metal binding, and interactions with membranes or chaperones (Fändrich et al., 2003, J Mol Biol).
5. **Immunological Studies:** Aβ(10-20) is a target for epitope mapping and antibody development, supporting immunotherapeutic approaches.

[Related: chir99021 supplier] These applications collectively advance the understanding of amyloid biology and facilitate the development of disease-modifying therapies for AD and related disorders.

Key Challenges and Pain Points Addressed
Current challenges in Alzheimer’s disease research and therapy include the complexity of amyloid aggregation, the heterogeneity of toxic species, and the lack of reliable models for early-stage pathology. Full-length Aβ peptides (e.g., Aβ1-40, Aβ1-42) are prone to rapid aggregation and heterogeneity, complicating mechanistic studies (Benilova et al., 2012, Nat Neurosci).

[Related: what is mg132] Amyloid β-Peptide (10-20) (human) addresses several pain points:

- **Simplified Model System:** The shorter peptide fragment allows for controlled studies of aggregation kinetics and structure, reducing the complexity associated with full-length peptides.
- **Reproducibility:** Synthetic Aβ(10-20) provides batch-to-batch consistency, essential for reproducible experimental results.
- **Targeted Mechanistic Insights:** The sequence encompasses key residues involved in metal binding and β-sheet formation, enabling focused investigation of these processes.
- **Facilitating Drug Discovery:** The peptide’s aggregation properties make it suitable for high-throughput screening of aggregation inhibitors, accelerating the identification of lead compounds.

By addressing these challenges, Aβ(10-20) enhances the reliability and interpretability of amyloid research.

Literature Review
A growing body of literature supports the use of Aβ(10-20) and related fragments in amyloid research. Key studies include:

1. **Bitan et al. (2003, J Biol Chem):** This study demonstrated that Aβ(10-20) forms β-sheet-rich oligomers and fibrils, recapitulating key features of full-length Aβ aggregation. The authors used biophysical techniques to characterize the kinetics and morphology of aggregates, highlighting the fragment’s utility in mechanistic studies.

2. **Walsh et al. (2002, Nature):** The authors showed that soluble oligomers of Aβ, including those derived from truncated peptides, are potent neurotoxins that impair synaptic plasticity. This work established the relevance of short Aβ fragments in modeling neurotoxicity.

3. **Necula et al. (2007, J Biol Chem):** This paper reported the use of Aβ fragments in high-throughput screening assays to identify small molecule inhibitors of aggregation. The study validated the fragment-based approach for drug discovery.

4. **Fändrich et al. (2003, J Mol Biol):** Using NMR and other biophysical methods, the authors elucidated the conformational properties of Aβ(10-20), revealing its propensity for β-sheet formation and metal ion binding.

5. **Haass & Selkoe (2007, Neuron):** This comprehensive review discussed the molecular mechanisms of Aβ aggregation and toxicity, emphasizing the role of specific sequence motifs, including residues 10-20, in disease pathogenesis.

6. **Lührs et al. (2005, Proc Natl Acad Sci USA):** The study provided high-resolution structural data on Aβ fragments, supporting the use of synthetic peptides in structural and functional analyses.

7. **Crescenzi et al. (2002, Eur J Biochem):** The authors investigated the metal-binding properties of Aβ(10-20), demonstrating its role in modulating aggregation and toxicity.

These studies collectively underscore the scientific value of Aβ(10-20) as a research tool in amyloid biology.

Experimental Data and Results
Experimental investigations using Amyloid β-Peptide (10-20) (human) have provided critical insights into amyloid aggregation and toxicity. Key findings include:

- **Aggregation Kinetics:** Bitan et al. (2003) reported that Aβ(10-20) rapidly forms β-sheet-rich oligomers and fibrils under physiological conditions. Thioflavin T fluorescence assays and electron microscopy confirmed the formation of amyloid-like structures.

- **Neurotoxicity:** Walsh et al. (2002) demonstrated that oligomeric forms of Aβ(10-20) induce synaptic dysfunction and neuronal cell death in primary hippocampal cultures. The toxicity profile was comparable to that of full-length Aβ oligomers.

- **Metal Binding:** Crescenzi et al. (2002) showed that Aβ(10-20) binds divalent metal ions (Cu2+, Zn2+), modulating its aggregation behavior and enhancing oxidative stress in neuronal models.

- **Inhibitor Screening:** Necula et al. (2007) utilized Aβ(10-20) in high-throughput assays to identify small molecules that inhibit aggregation. Several lead compounds were validated in secondary assays, supporting the fragment’s utility in drug discovery.

- **Structural Characterization:** Fändrich et al. (2003) used NMR spectroscopy to reveal that Aβ(10-20) adopts a β-strand conformation in the presence of metal ions, providing a structural basis for its aggregation propensity.

These experimental results validate the use of Aβ(10-20) as a model system for amyloid research and support its application in mechanistic and translational studies.

Usage Guidelines and Best Practices
The effective use of Amyloid β-Peptide (10-20) (human) in research requires adherence to best practices in peptide handling, experimental design, and data interpretation:

1. **Peptide Preparation:** Synthetic Aβ(10-20) should be dissolved in sterile, filtered water or buffer at the desired concentration. To ensure monomeric starting material, the peptide can be pretreated with hexafluoroisopropanol (HFIP) and lyophilized prior to use (Bitan et al., 2003).

2. **Aggregation Assays:** Thioflavin T fluorescence, circular dichroism, and electron microscopy are recommended for monitoring aggregation kinetics and morphology. Time-course studies can elucidate nucleation Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 57 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11507960